{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:58:06Z","timestamp":1793656686638,"version":"4.5.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"AstraZeneca Pharmaceuticals LP","award":["ESR-20-20653"],"award-info":[{"award-number":["ESR-20-20653"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-025-02875-6","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T20:58:33Z","timestamp":1753909113000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of dapagliflozin in patients hospitalized with COVID-19 with and without type 2 diabetes: a prespecified analysis of the DARE-19 randomized trial"],"prefix":"10.1186","volume":"24","author":[{"given":"Mohammad","family":"Abdel Jawad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remo H. M.","family":"Furtado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Esterline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Oscarsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samvel B.","family":"Gasparyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary G.","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Mukhtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subodh","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Langkilde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Ambery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shachi","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensey","family":"Gosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheryl L.","family":"Windsor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronaldo V. P.","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diogo D. F.","family":"Moia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Aboudara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Javaheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. F. Kerr","family":"Saraiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilia Nigro","family":"Maia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otavio","family":"Berwanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail N.","family":"Kosiborod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"2875_CR1","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S2213-8587(24)00102-5","volume":"12","author":"MS Usman","year":"2024","unstructured":"Usman MS, Bhatt DL, Hameed I, Anker SD, Cheng AYY, Hernandez AF, Jones WS, Khan MS, Petrie MC, Udell JA, Friede T, Butler J. Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2024;12:447\u201361.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2875_CR2","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS, Investigators D-T. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347\u201357.","journal-title":"N Engl J Med"},{"key":"2875_CR3","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12933-017-0621-8","volume":"16","author":"A Solini","year":"2017","unstructured":"Solini A, Giannini L, Seghieri M, Vitolo E, Taddei S, Ghiadoni L, Bruno RM. Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study. Cardiovasc Diabetol. 2017;16:138.","journal-title":"Cardiovasc Diabetol"},{"key":"2875_CR4","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.diabet.2018.09.005","volume":"44","author":"F Bonnet","year":"2018","unstructured":"Bonnet F, Scheen AJ. Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: the potential contribution to diabetes complications and cardiovascular disease. Diabetes Metab. 2018;44:457\u201364.","journal-title":"Diabetes Metab"},{"key":"2875_CR5","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s10787-020-00732-4","volume":"29","author":"ZH Maayah","year":"2021","unstructured":"Maayah ZH, Ferdaoussi M, Takahara S, Soni S, Dyck JRB. Empagliflozin suppresses inflammation and protects against acute septic renal injury. Inflammopharmacology. 2021;29:269\u201379.","journal-title":"Inflammopharmacology"},{"key":"2875_CR6","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.biochi.2020.11.010","volume":"180","author":"P Icard","year":"2021","unstructured":"Icard P, Lincet H, Wu Z, Coquerel A, Forgez P, Alifano M, Fournel L. The key role of Warburg effect in SARS-CoV-2 replication and associated inflammatory response. Biochimie. 2021;180:169\u201377.","journal-title":"Biochimie"},{"key":"2875_CR7","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1111\/dom.14296","volume":"23","author":"M Kosiborod","year":"2021","unstructured":"Kosiborod M, Berwanger O, Koch GG, Martinez F, Mukhtar O, Verma S, Chopra V, Javaheri A, Ambery P, Gasparyan SB, Buenconsejo J, Sj\u00f6str\u00f6m CD, Langkilde AM, Oscarsson J, Esterline R. Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: design and rationale for the DARE-19 study. Diabetes Obes Metab. 2021;23:886\u201396.","journal-title":"Diabetes Obes Metab"},{"key":"2875_CR8","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/S2213-8587(21)00180-7","volume":"9","author":"MN Kosiborod","year":"2021","unstructured":"Kosiborod MN, Esterline R, Furtado RHM, Oscarsson J, Gasparyan SB, Koch GG, Martinez F, Mukhtar O, Verma S, Chopra V, Buenconsejo J, Langkilde AM, Ambery P, Tang F, Gosch K, Windsor SL, Akin EE, Soares RVP, Moia DDF, Aboudara M, Hoffmann Filho CR, Feitosa ADM, Fonseca A, Garla V, Gordon RA, Javaheri A, Jaeger CP, Leaes PE, Nassif M, Pursley M, Silveira FS, Barroso WKS, Lazcano Soto JR, Nigro Maia L, Berwanger O. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2021;9:586\u201394.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2875_CR9","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/S2213-8587(24)00218-3","volume":"12","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod MN, Windsor SL, Vardeny O, Berger JS, Reynolds HR, Boumakis S, Althouse AD, Solomon SD, Bhatt AS, Peikert A, Luther JF, Leifer ES, Kindzelski AL, Cushman M, Ng Gong M, Kornblith LZ, Khatri P, Kim KS, Baumann Kreuziger L, Javaheri A, Carpio C, Wahid L, Lopez-Sendon Moreno J, Alonso A, Ho MQ, Lopez-Sendon J, Lopes RD, Curtis JL, Kirwan BA, Geraci MW, Neal MD, Hochman JS. Effect of sodium-glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, platform trial. Lancet Diabetes Endocrinol. 2024;12:725\u201334.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2875_CR10","unstructured":"Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet Diabetes Endocrinol 2023;11:905\u2013914"},{"key":"2875_CR11","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1001\/jama.2024.10510","volume":"332","author":"CAM Tavares","year":"2024","unstructured":"Tavares CAM, Azevedo LCP, Rea-Neto \u00c1, Campos NS, Amendola CP, Kozesinski-Nakatani AC, David-Jo\u00e3o PG, Lobo SM, Filiponi TC, Almeida GMB, Bergo RR, Guimar\u00e3es-J\u00fanior MRR, Figueiredo RC, Castro JR, Schuler CJ, Westphal GA, Carioca ACR, Monfradini F, Nieri J, Neves FMO, Paulo JA, Albuquerque CSN, Silva MCR, Kosiborod MN, Pereira AJ, Damiani LP, Corr\u00eaa TD, Serpa-Neto A, Berwanger O, Zampieri FG. Dapagliflozin for critically ill patients with acute organ dysfunction: the DEFENDER randomized clinical trial. JAMA. 2024;332:401\u201311.","journal-title":"JAMA"},{"key":"2875_CR12","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S2213-8587(24)00219-5","volume":"12","author":"C Vale","year":"2024","unstructured":"Vale C, Godolphin PJ, Fisher D, Horby PW, Kosiborod MN, Hochman JS, Webster K, Higgins JPT, Althouse AD, Berwanger O, Furtado RHM, Gasparyan SB, Haynes R, Koch GG, Landray M, Leifer E, Marshall J, Murthy S, Neal MD, Staplin N, Diaz J, Sterne JAC, Shankar-Hari M. Sodium-glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2024;12:735\u201347.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2875_CR13","doi-asserted-by":"publisher","first-page":"e1063","DOI":"10.1097\/CCM.0000000000005337","volume":"49","author":"L Evans","year":"2021","unstructured":"Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, Machado FR, McIntyre L, Ostermann M, Prescott HC, Schorr C, Simpson S, Wiersinga WJ, Alshamsi F, Angus DC, Arabi Y, Azevedo L, Beale R, Beilman G, Belley-Cote E, Burry L, Cecconi M, Centofanti J, Coz Yataco A, De Waele J, Dellinger RP, Doi K, Du B, Estenssoro E, Ferrer R, Gomersall C, Hodgson C, Hylander M\u00f8ller M, Iwashyna T, Jacob S, Kleinpell R, Klompas M, Koh Y, Kumar A, Kwizera A, Lobo S, Masur H, McGloughlin S, Mehta S, Mehta Y, Mer M, Nunnally M, Oczkowski S, Osborn T, Papathanassoglou E, Perner A, Puskarich M, Roberts J, Schweickert W, Seckel M, Sevransky J, Sprung CL, Welte T, Zimmerman J, Levy M. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Crit Care Med. 2021;49:e1063\u2013143.","journal-title":"Crit Care Med"},{"key":"2875_CR14","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s43441-022-00420-1","volume":"56","author":"SB Gasparyan","year":"2022","unstructured":"Gasparyan SB, Buenconsejo J, Kowalewski EK, Oscarsson J, Bengtsson OF, Esterline R, Koch GG, Berwanger O, Kosiborod MN. Design and analysis of studies based on hierarchical composite endpoints: insights from the DARE-19 trial. Ther Innov Regul Sci. 2022;56:785\u201394.","journal-title":"Ther Innov Regul Sci"},{"key":"2875_CR15","doi-asserted-by":"crossref","unstructured":"Gasparyan B, Kowalewski E, Buenconsejo J, Koch G. Case Studies in Innovative Clinical Trials (1st ed.), Hierarchical composite endpoints in COVID-19: The DARE-19 Trial. 2023, p. 95\u2013148","DOI":"10.1201\/9781003288640-7"},{"key":"2875_CR16","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1177\/0962280220942558","volume":"30","author":"SB Gasparyan","year":"2021","unstructured":"Gasparyan SB, Folkvaljon F, Bengtsson O, Buenconsejo J, Koch GG. Adjusted win ratio with stratification: calculation methods and interpretation. Stat Methods Med Res. 2021;30:580\u2013611.","journal-title":"Stat Methods Med Res"},{"key":"2875_CR17","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1210\/jc.2015-1884","volume":"100","author":"SI Taylor","year":"2015","unstructured":"Taylor SI, Blau JE, Rother KI. Sglt2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab. 2015;100:2849\u201352.","journal-title":"J Clin Endocrinol Metab"},{"key":"2875_CR18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1152\/ajplegacy.1955.184.1.91","volume":"184","author":"JJ Cohen","year":"1956","unstructured":"Cohen JJ, Berglund F, Lotspeich WD. Renal tubular reabsorption of acetoacetate, inorganic sulfate and inorganic phosphate in the dog as affected by glucose and phlorizin. Am J Physiol. 1956;184:91\u20136.","journal-title":"Am J Physiol"},{"key":"2875_CR19","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, B\u011blohl\u00e1vek J, B\u00f6hm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Duk\u00e1t A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O\u2019Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sj\u00f6strand M, Langkilde AM. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995\u20132008.","journal-title":"N Engl J Med"},{"key":"2875_CR20","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S2213-8587(21)00208-4","volume":"9","author":"S Misra","year":"2021","unstructured":"Misra S, Barron E, Vamos E, Thomas S, Dhatariya K, Kar P, Young B, Khunti K, Valabhji J. Temporal trends in emergency admissions for diabetic ketoacidosis in people with diabetes in England before and during the COVID-19 pandemic: a population-based study. Lancet Diabetes Endocrinol. 2021;9:671\u201380.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2875_CR21","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1001\/jama.2020.1906","volume":"323","author":"MC Petrie","year":"2020","unstructured":"Petrie MC, Verma S, Docherty KF, Inzucchi SE, Anand I, Belohl\u00e1vek J, B\u00f6hm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Duk\u00e1t A, Ge J, Howlett J, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O\u2019Meara E, Vinh PN, Schou M, Tereshchenko S, K\u00f8ber L, Kosiborod MN, Langkilde AM, Martinez FA, Ponikowski P, Sabatine MS, Sj\u00f6strand M, Solomon SD, Johanson P, Greasley PJ, Boulton D, Bengtsson O, Jhund PS, McMurray JJV. Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA. 2020;323:1353\u201368.","journal-title":"JAMA"},{"key":"2875_CR22","doi-asserted-by":"publisher","first-page":"973129","DOI":"10.3389\/fcvm.2022.973129","volume":"9","author":"X Rong","year":"2022","unstructured":"Rong X, Zhu Y, Wen B, Liu K, Li X, Gou Q, Chen X. Risk of hypovolemia associated with sodium-glucose cotransporter-2 inhibitors treatment: a meta-analysis of randomized controlled trials. Front Cardiovasc Med. 2022;9:973129.","journal-title":"Front Cardiovasc Med"},{"key":"2875_CR23","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3132\/dvdr.2008.039","volume":"5","author":"M Kosiborod","year":"2008","unstructured":"Kosiborod M. Blood glucose and its prognostic implications in patients hospitalised with acute myocardial infarction. Diab Vasc Dis Res. 2008;5:269\u201375.","journal-title":"Diab Vasc Dis Res"},{"key":"2875_CR24","doi-asserted-by":"publisher","first-page":"S244","DOI":"10.2337\/dc22-S016","volume":"45","author":"Diabetes Care in the Hospital","year":"2022","unstructured":"Diabetes Care in the Hospital. Standards of medical care in diabetes-2022. Diabetes Care. 2022;45:S244-s253.","journal-title":"Diabetes Care"},{"key":"2875_CR25","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1161\/CIRCOUTCOMES.109.887620","volume":"3","author":"KJ Lipska","year":"2010","unstructured":"Lipska KJ, Wang Y, Kosiborod M, Masoudi FA, Havranek EP, Krumholz HM, Inzucchi SE. Discontinuation of antihyperglycemic therapy and clinical outcomes after acute myocardial infarction in older patients with diabetes. Circ Cardiovasc Qual Outcomes. 2010;3:236\u201342.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2875_CR26","doi-asserted-by":"publisher","first-page":"100617","DOI":"10.1016\/j.lanepe.2023.100617","volume":"29","author":"ME Malik","year":"2023","unstructured":"Malik ME, Falkentoft AC, Jensen J, Zahir D, Parveen S, Alhakak A, Andersson C, Petrie MC, Sattar N, McMurray JJV, K\u00f8ber L, Schou M. Discontinuation and reinitiation of SGLT-2 inhibitors and GLP-1R agonists in patients with type 2 diabetes: a nationwide study from 2013 to 2021. Lancet Reg Health Eur. 2023;29:100617.","journal-title":"Lancet Reg Health Eur"},{"key":"2875_CR27","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1161\/CIRCULATIONAHA.123.065748","volume":"148","author":"M Packer","year":"2023","unstructured":"Packer M, Butler J, Zeller C, Pocock SJ, Brueckmann M, Ferreira JP, Filippatos G, Usman MS, Zannad F, Anker SD. Blinded withdrawal of long-term randomized treatment with Empagliflozin or placebo in patients with heart failure. Circulation. 2023;148:1011\u201322.","journal-title":"Circulation"},{"key":"2875_CR28","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.ahj.2013.03.007","volume":"165","author":"LH Curtis","year":"2013","unstructured":"Curtis LH, Mi X, Qualls LG, Check DK, Hammill BG, Hammill SC, Heidenreich PA, Masoudi FA, Setoguchi S, Hernandez AF, Fonarow GC. Transitional adherence and persistence in the use of aldosterone antagonist therapy in patients with heart failure. Am Heart J. 2013;165:979-986.e971.","journal-title":"Am Heart J"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02875-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-025-02875-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02875-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T07:53:23Z","timestamp":1757318003000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02875-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2875"],"URL":"https:\/\/doi.org\/10.1186\/s12933-025-02875-6","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,30]]},"assertion":[{"value":"28 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This trial was approved by ethics committees at all study sites, and all participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All participantswere informed the results from this trial may be presented in articles when they provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Kosiborod: Grant\/Research Support: Astra Zeneca, Boehringer Ingelheim and Pfizer. Honoraria: Astra Zeneca, Boehringer Ingelheim, Novo Nordisk. Consultant\/Advisory Boards: 35Pharma, Alnylam, Amgen, Applied Therapeutics, Arrowhead Pharmaceuticals, Astra Zeneca, Bayer, Boehringer Ingelheim, Corcept Therapeutics, Cytokinetics, Dexcom, Eli Lilly, Esperion Therapeutics, Imbria Pharmaceuticals, Janssen, Lexicon Pharmaceuticals, Merck (Diabetes and Cardiovascular), Novo Nordisk, Pfizer, Pharmacosmos, Regeneron, Roche, Sanofi, scPharmaceuticals, Structure Therapeutics, Vifor Pharma, Youngene Therapeutics. Stock options: Artera Health, Saghmos Therapeutics. Employment: AstraZeneca R&D, effective January 6, 2025. Dr. Sauer: Research Funding (Site Fees): AstraZeneca, CSL Vifor, NovoNordisk, Pfizer, RivusConsultant: 35Pharma, Abbott, Acorai, Amgen, Bayer, Boston Scientific, CSL Vifor, General Prognostics, Impulse Dynamics, Rivus, Story Health. Other Research Support (Data Analytic Center Fees): AstraZeneca, Vifor Pharma. Stock ownership: ISHI, Pulsli. Dr. Furtado reports research grants and personal fees from AstraZeneca, Bayer, Servier, and Apsen; and research grants (received from his institution) from Pfizer, Libbs, Brazilian Ministry of Health, and University Health Network. Drs. Oscarsson, Gasparyan, Esterline, Langkilde, and Ambery are shareholders and employed by AstraZeneca. Professor Gary G. Koch: Grant\/Research Support: AbbVie, Acadia Pharmaceuticals, Aerovate Therapeutics, Amgen, AstraZeneca, Bayer, BioMarin, Cytokinetics, ENSHO, Galderma Research Development, Gilead, GlaxoSmithKline, HUYA Bioscience International, Intracellular Therapies, Ironwood, Johnson and Johnson, Kala, Merck, Momentum, Novartis, Otsuka, Pfizer, Regeneron Pharmaceuticals, REGENXBIO Inc, Renovion, Scholar Rock, Summit Therapeutics, UCB, vTv Therapeutics, Xylocor Therapeutics. The other authors report no disclosures.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"307"}}